We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment... Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States. Show more
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights PR Newswire CAMBRIDGE, Mass., May 9, 2024 Akebia to host conference call at 8:00 a.m. ET on May...
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights PR Newswire CAMBRIDGE, Mass., May 2, 2024 Akebia to Host Conference Call on May 9, 2024...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., May 1, 2024 CAMBRIDGE, Mass., May 1, 2024 /PRNewswire/ -- Akebia Therapeutics...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., April 2, 2024 CAMBRIDGE, Mass., April 2, 2024 /PRNewswire/ -- Akebia Therapeutics...
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis PR Newswire CAMBRIDGE, Mass., March 27, 2024...
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights PR Newswire CAMBRIDGE, Mass., March 14, 2024 Potential vadadustat U.S. approval on...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.03 | 2.38095238095 | 1.26 | 1.56 | 1.03 | 2972305 | 1.38913753 | CS |
4 | -0.26 | -16.7741935484 | 1.55 | 1.56 | 1.03 | 2901142 | 1.37322888 | CS |
12 | -0.24 | -15.6862745098 | 1.53 | 2.48 | 1.03 | 5182406 | 1.67495332 | CS |
26 | 0.32 | 32.9896907216 | 0.97 | 2.48 | 0.88 | 3265544 | 1.59576401 | CS |
52 | 0.27 | 26.4705882353 | 1.02 | 2.48 | 0.7801 | 2531471 | 1.44980648 | CS |
156 | -1.76 | -57.7049180328 | 3.05 | 4.33 | 0.241 | 3774534 | 1.30118292 | CS |
260 | -4.33 | -77.0462633452 | 5.62 | 13.78 | 0.241 | 3495313 | 2.40554067 | CS |
Symbol | Price | Vol. |
---|---|---|
GWAVGreenwave Technology Solutions Inc | $ 0.0692 (19.10%) | 154.93M |
SGDSafe and Green Development Corporation | $ 0.7725 (24.60%) | 94.1M |
SQQQProShares UltraPro Short QQQ | $ 10.70 (-0.37%) | 75.18M |
CPOPPop Culture Group Company Ltd | $ 2.9201 (71.77%) | 72.67M |
FFIEFaraday Future Intelligent Electric Inc | $ 0.0403 (-3.59%) | 67.88M |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions